---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Care management intervention strategies"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Care management intervention strategies. Topics: Prophylaxis and treatment of acneiform dermatitis in the phase 1b cohort, Protocol prophylactic skin measures and suggested treatment of rash, Company description of rash management, Premedication and management of infusion-related reactions, and 7 further topics. 11 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Prophylaxis and treatment of acneiform dermatitis in the phase 1b cohort

> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”
> “Ficerafusp alfa was interrupted because of dermatologic TRAEs in eight patients (19%). Supportive care administered by investigators included topical steroid and antibiotics. No patient discontinued treatment because of dermatitis acneiform or rash TRAEs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-2"></a>

### Protocol prophylactic skin measures and suggested treatment of rash

> “Prophylactic measures may include but are not limited to: using sunscreen, limiting sun exposure, avoiding hot water/alcohol-based cosmetics that can produce dry skin, using bath oils to enhance skin hydration, using alcohol-free moisturizing creams frequently, using tocopherol oil or gel, avoiding tight shoes to prevent friction/pressure on the nail fold, avoiding excessive beard growth, shaving with regular shaving razor/sharp multiblade, using pre-shaving cream emollients and moisturizing aftershave, avoiding electric shaver.”
> “Antibiotics: clindamycin 1% gel, erythromycin 3% gel/cream, metronidazole 0.75%–1% cream/gel, twice/day until regression to Grade 1 (avoid benzoyl peroxide products).”
> “Antibiotics: minocycline 100 mg orally once/day, doxycycline 100 mg orally once/day for ≥4 weeks until the rash is symptomatic”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

<a id="topic-2.2.2.4-3"></a>

### Company description of rash management

> “It is mechanistically related to anti-EGFR activity and is typically well mitigated by treating physicians with the use of steroids and other topicals.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.2.2.4-4"></a>

### Premedication and management of infusion-related reactions

> “Mandatory premedication regimen 30 to 60 minutes prior to each BCA101 infusion includes”
> “25-50 mg PO diphenhydramine and”
> “500-650 mg PO paracetamol (acetaminophen) will be given or oral equivalent.”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

> “The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-5"></a>

### Supportive care for anemia

> “Supportive care administered by investigators included iron supplementation and transfusion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-6"></a>

### Mitigation strategies carried into later trials

> “Safety findings from this phase I/Ib study have informed the design of subsequent studies of ficerafusp alfa and pembrolizumab, including mitigation strategies for AEs of special interest.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.4-7"></a>

### Multidisciplinary team discussion

> “Ideally the optimal treatment strategy should be discussed in an MDT including not only the treating physicians but all the supportive specialities”

Source: [Keam et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8710460/)

<a id="topic-2.2.2.4-8"></a>

### HPV testing by primary site

> “For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.”
> “Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management”

Source: [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)

> “For oropharyngeal cancer, p16 IHC is strongly recommended”
> “For recurrent and/or metastatic SCCHN, tumour PD-L1 expression should be evaluated”

Source: [Keam et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8710460/)

<a id="topic-2.2.2.4-9"></a>

### PD-L1 testing for pembrolizumab monotherapy

> “as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.4-10"></a>

### HPV and PD-L1 testing in the pivotal trial

> “Participant has documentation of HPV-negative disease per central testing performed if presenting with OPSCC.”
> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (PD-L1 immunohistochemistry [IHC] via 22C3).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-2.2.2.4-11"></a>

### HPV testing method in the phase 1b protocol

> “Subjects presenting with a history of oropharyngeal cancer, must have results from testing of HPV status, defined as p16 expression by IHC analysis.”
> “Subjects with hypopharynx, larynx and oral cavity cancer are not required to undergo HPV testing by p16 IHC.”

Source: [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
